Dova Pharmaceuticals to Host Investor & Analyst Day on September 20, 2018
September 11, 2018 16:45 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates...
Dova Pharmaceuticals Submits Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic ITP
September 04, 2018 16:05 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates...
Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results
August 09, 2018 16:01 ET
|
Dova Pharmaceuticals, Inc.
DOPTELET approved by FDA on May 21, 2018 DOPTELET launched on June 4, 2018 Conference call scheduled for 4:30 p.m. ET today Investor & Analyst Day scheduled for September 20, 2018 in NYC ...
Dova Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 9, 2018
July 26, 2018 16:05 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., July 26, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Thursday, August 9, 2018 at 4:30 p.m. ET to discuss second quarter 2018...
Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors
June 25, 2018 07:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Nancy J. Wysenski will join Dova’s Board of Directors effective immediately. In addition...
Dova Pharmaceuticals Announces Publication of Pivotal Phase 3 Data and Upcoming Congress Presentations for DOPTELET® (avatrombopag)
June 04, 2018 07:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., June 04, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the recent online publication of its pivotal Phase 3 trial data on the use of DOPTELET® ...
Dova Pharmaceuticals Announces Availability of DOPTELET® in the United States
May 31, 2018 07:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., May 31, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the availability of DOPTELET in the United States for the treatment of thrombocytopenia in...
Dova Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference
May 29, 2018 17:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the...
Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag)
May 21, 2018 12:43 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., May 21, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the U.S. Food and Drug Administration (FDA) has completed their Priority Review and approved...
Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results
May 09, 2018 16:05 ET
|
Dova Pharmaceuticals, Inc.
PDUFA date for avatrombopag of May 21, 2018 Conference call scheduled for 4:30 p.m. ET today DURHAM, N.C., May 09, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a...